[go: up one dir, main page]

ES2599153T3 - Molécula de ARNi para la timidilato sintasa y uso de la misma - Google Patents

Molécula de ARNi para la timidilato sintasa y uso de la misma Download PDF

Info

Publication number
ES2599153T3
ES2599153T3 ES10758615.8T ES10758615T ES2599153T3 ES 2599153 T3 ES2599153 T3 ES 2599153T3 ES 10758615 T ES10758615 T ES 10758615T ES 2599153 T3 ES2599153 T3 ES 2599153T3
Authority
ES
Spain
Prior art keywords
thymidylate synthase
rnai molecule
seq
nucleotide sequence
rnai
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10758615.8T
Other languages
English (en)
Inventor
Hiromi Wada
Cheng Long HUANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Delta Fly Pharma Inc
Original Assignee
Delta Fly Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delta Fly Pharma Inc filed Critical Delta Fly Pharma Inc
Application granted granted Critical
Publication of ES2599153T3 publication Critical patent/ES2599153T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/01—Methyltransferases (2.1.1)
    • C12Y201/01045—Thymidylate synthase (2.1.1.45)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

Una molécula de ARNi que es capaz de suprimir la expresión de la timidilato sintasa por la acción de un ARNi que comprende un dominio de ARN de doble cadena compuesto por una cadena con sentido que consiste en la secuencia de nucleótidos representada por SEQ ID NO: 1 hibridada con una cadena antisentido que consiste en la secuencia de nucleótidos representada por SEQ ID NO: 2, en donde la cadena con sentido está unida a la cadena antisentido mediante una región enlazadora.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8

Claims (1)

  1. imagen1
ES10758615.8T 2009-03-31 2010-03-29 Molécula de ARNi para la timidilato sintasa y uso de la misma Active ES2599153T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009086463 2009-03-31
JP2009086463 2009-03-31
PCT/JP2010/055521 WO2010113844A1 (ja) 2009-03-31 2010-03-29 チミジル酸合成酵素に対するＲＮＡｉ分子およびその用途

Publications (1)

Publication Number Publication Date
ES2599153T3 true ES2599153T3 (es) 2017-01-31

Family

ID=42828134

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10758615.8T Active ES2599153T3 (es) 2009-03-31 2010-03-29 Molécula de ARNi para la timidilato sintasa y uso de la misma

Country Status (14)

Country Link
US (1) US8524876B2 (es)
EP (1) EP2415870B1 (es)
JP (1) JP5687188B2 (es)
KR (1) KR101579638B1 (es)
CN (2) CN107090454A (es)
DK (1) DK2415870T3 (es)
ES (1) ES2599153T3 (es)
HR (1) HRP20161293T1 (es)
HU (1) HUE029171T2 (es)
PL (1) PL2415870T3 (es)
PT (1) PT2415870T (es)
RU (1) RU2535993C2 (es)
TW (1) TWI526211B (es)
WO (1) WO2010113844A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120301537A1 (en) * 2011-05-23 2012-11-29 Delta-Fly Pharma, Inc. LIPOSOME CONTAINING shRNA MOLECULE TARGETING A THYMIDYLATE SYNTHASE AND USE THEREOF
US8592572B2 (en) 2011-05-23 2013-11-26 Delta-Fly Pharma, Inc. Liposome containing shRNA molecule targeting a thymidylate synthase and use thereof
US20140255471A1 (en) 2013-03-11 2014-09-11 Wake Forest University Health Sciences Method of treating brain tumors
HUE040425T2 (hu) 2013-04-30 2019-03-28 Delta Fly Pharma Inc Liposzóma topikális adagoláshoz és alkalmazása
AU2015337909B2 (en) 2014-10-30 2018-12-13 Delta-Fly Pharma, Inc. New production method of lipoplex for local administration and antitumor drug using lipoplex
JP2023167428A (ja) 2022-05-12 2023-11-24 コニカミノルタ株式会社 光学フィルムの製造方法、光学フィルム、偏光板及び液晶表示装置

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4910510B1 (es) 1968-01-26 1974-03-11
KR0148589B1 (ko) 1991-05-27 1998-11-02 고바야시 유끼오 항종양 효과의 상승 및 종양의 치료를 위한 조성물 및 키트
RU2279277C2 (ru) * 2000-03-31 2006-07-10 Энджиоджен Фармасьютикалз Лтд. Лечение разделенными дозами агентов с сосудоразрушающей активностью
EP1511769A2 (en) * 2002-05-15 2005-03-09 Birgit Luber Egf receptor antagonists in the treatment of gastric cancer
DK2284266T3 (da) * 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc sIRNA-MOLEKYLE MOD TP53
JP2007513611A (ja) * 2003-11-26 2007-05-31 ザ クイーンズ ユニヴァーシティ オブ ベルファスト 癌治療
JP4543188B2 (ja) 2004-03-10 2010-09-15 学校法人日本医科大学 ヒトチミジル酸合成酵素に対するＲＮＡｉとして作用するＲＮＡ配列
KR100844477B1 (ko) * 2004-06-09 2008-07-07 다이호야쿠힌고교 가부시키가이샤 항종양 효과 증강제, 항종양제 및 암 치료 방법
JP5139067B2 (ja) * 2005-09-14 2013-02-06 タカラバイオ株式会社 ｓｈＲＮＡ発現のための有効な新規ループ配列
JP4837043B2 (ja) 2006-09-19 2011-12-14 三菱電機株式会社 アクチュエータ
JPWO2008035461A1 (ja) 2006-09-22 2010-01-28 大鵬薬品工業株式会社 胃癌の術後補助化学治療法
WO2008124927A1 (en) * 2007-04-13 2008-10-23 Vincent Research & Consulting Inc. Sirna against thymidylate synthase and uses thereof in cancer treatment regimens
JP2009086463A (ja) 2007-10-01 2009-04-23 Fuji Xerox Co Ltd 無端状部材回転駆動装置および画像形成装置

Also Published As

Publication number Publication date
PL2415870T3 (pl) 2017-01-31
PT2415870T (pt) 2016-10-25
RU2535993C2 (ru) 2014-12-20
WO2010113844A1 (ja) 2010-10-07
EP2415870A9 (en) 2012-07-11
TWI526211B (zh) 2016-03-21
TW201038278A (en) 2010-11-01
JPWO2010113844A1 (ja) 2012-10-11
JP5687188B2 (ja) 2015-03-18
EP2415870B1 (en) 2016-07-20
EP2415870A1 (en) 2012-02-08
US20120016012A1 (en) 2012-01-19
HRP20161293T1 (hr) 2016-11-18
US8524876B2 (en) 2013-09-03
CN102369283A (zh) 2012-03-07
DK2415870T3 (en) 2016-10-10
KR101579638B1 (ko) 2015-12-22
CN107090454A (zh) 2017-08-25
EP2415870A4 (en) 2012-11-28
KR20110135980A (ko) 2011-12-20
RU2011143753A (ru) 2013-05-10
HUE029171T2 (hu) 2017-02-28

Similar Documents

Publication Publication Date Title
ES2599153T3 (es) Molécula de ARNi para la timidilato sintasa y uso de la misma
ES2548018T3 (es) Composiciones que comprenden 2,3,3,3-tetrafluoropropeno e hidrocarburos y usos de las mismas
ES2481040T3 (es) Oligonucleótidos inmunoestimulantes
ES2509890T3 (es) Sustancias y composiciones para potenciar la reparación de ADN y procedimientos de uso
CA3027780C (en) Reduced size self-delivering rnai compounds
HK1200484A1 (zh) 多聚寡核苷酸化合物
MX390699B (es) Composiciones y metodos para inhibicion de genes para apolipoproteina c-iii (apoc3).
CY1120495T1 (el) Ολιγονουκλεοτιδικα anaλoγα που στοχευουν το ανθρωπινο lmna
MX2017008500A (es) Supresión del gen de la huntingtina inducida por la arni.
WO2011008730A3 (en) Chemical modification of small hairpin rnas for inhibition of gene expression
CA2884608C (en) MULTIMERIC OLIGONUCLEOTIDE COMPOUNDS
BRPI1010689A2 (pt) "dsrna formulado por lipídios direcionados para o gene pcsk9"
EP2647644A4 (en) 2'-O-MODIFIED RNA
BRPI0907008A2 (pt) Métodos otimizados para liberação de dsrna alvejando o gene pcsk9
MX355408B (es) Inhibidores a base de oligonucleotidos que comprenden un motivo de acido nucleico bloqueado.
ECSP099794A (es) INHIBICIÓN DE ARNi DE EXPRESIÓN DE ALFA-ENaC
ECSP11010803A (es) Compuestos de cobre nanoparticulados
AR069821A1 (es) Composiciones y metodos de uso de la interferencia de arn para el control de nematodos
CL2011000098A1 (es) Uso de una betadefensina de mamifero para tratar enfermedad inflamatoria.
ES2549192T3 (es) Construcción de expresión de ADN
BR112013002738A2 (pt) métodos e compostos para o diagnóstico e o tratamento do câncer
IT1399742B1 (it) Microorganismi inattivati contenenti molecole di rna a doppio filamento (dsrna), loro uso come pesticidi e metodi per la loro preparazione
CR11601A (es) Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteina quinasa
PA8814801A1 (es) Triazolopiridazinas como inhibidores de par1, su preparación y su uso como medicamentos
AR083445A1 (es) siARN CONTRA LA FIBROSIS